- Home
- UNCY vs CTSO Comparison
UNCY vs CTSO Comparison
Compare UNCY & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CTSO
- Stock Information
- Founded
- UNCY 2016
- CTSO 1997
- Country
- UNCY United States
- CTSO United States
- Employees
- UNCY N/A
- CTSO N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- UNCY Health Care
- CTSO Health Care
- Exchange
- UNCY Nasdaq
- CTSO Nasdaq
- Market Cap
- UNCY 58.7M
- CTSO 51.6M
- IPO Year
- UNCY 2021
- CTSO N/A
- Fundamental
- Price
- UNCY $0.62
- CTSO $1.15
- Analyst Decision
- UNCY Strong Buy
- CTSO Strong Buy
- Analyst Count
- UNCY 4
- CTSO 3
- Target Price
- UNCY $5.50
- CTSO $4.67
- AVG Volume (30 Days)
- UNCY 1.0M
- CTSO 147.4K
- Earning Date
- UNCY 03-27-2025
- CTSO 03-06-2025
- Dividend Yield
- UNCY N/A
- CTSO N/A
- EPS Growth
- UNCY N/A
- CTSO N/A
- EPS
- UNCY N/A
- CTSO N/A
- Revenue
- UNCY N/A
- CTSO $37,739,531.00
- Revenue This Year
- UNCY N/A
- CTSO $9.20
- Revenue Next Year
- UNCY N/A
- CTSO $11.64
- P/E Ratio
- UNCY N/A
- CTSO N/A
- Revenue Growth
- UNCY N/A
- CTSO 1.80
- 52 Week Low
- UNCY $0.20
- CTSO $0.70
- 52 Week High
- UNCY $1.80
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- UNCY 51.79
- CTSO 55.74
- Support Level
- UNCY $0.57
- CTSO $1.06
- Resistance Level
- UNCY $0.65
- CTSO $1.61
- Average True Range (ATR)
- UNCY 0.05
- CTSO 0.13
- MACD
- UNCY 0.01
- CTSO 0.01
- Stochastic Oscillator
- UNCY 76.36
- CTSO 29.34
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.